跳转至内容
Merck

M-136

Supelco

甲氨蝶呤,1 X 100MG 溶液

1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H22N8O5
CAS号:
分子量:
454.44
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

certified reference material

品質等級

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

1.0 mg/mL in methanol with 0.1N NaOH

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

pharmaceutical (small molecule)

格式

single component solution

儲存溫度

−20°C

SMILES 字串

O=C(C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)NC(C(O)=O)CCC(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)

InChI 密鑰

FBOZXECLQNJBKD-UHFFFAOYSA-N

一般說明

经认证的加标溶®液,用于通过HPLC或LC/MS进行治疗药物监测(TDM)分析。甲氨蝶呤用于癌症和自身免疫性疾病的治疗,是一种抗代谢和抗叶酸药物,由临床实验室监测,以确保患者保持在药物治疗范围内。Snap-N-Spike®格式允许实验室消除甲氨蝶呤等有害物质的称重操作,显著减少与处理急性毒性粉末有关的职业暴露危害,并提供在使用前将其加标到其选择的基质中的能力。

應用


  • Pharmacokinetic analysis: Methotrexate solution is employed in advanced pharmacokinetic studies using UV-Vis spectrophotometric and colorimetric methods. This application facilitates precise quantification in plasma and tissue, crucial for evaluating drug distribution and effectiveness in cancer treatments (Febrianti et al., 2024).

  • Toxicity and safety monitoring: Observational studies utilize Methotrexate solution to investigate root causes of medication errors and manage toxicity in elderly patients. This research supports safer clinical practices by identifying risk factors and improving patient safety protocols (Bisht et al., 2024).

  • Nephrotoxicity prevention: Research on Methotrexate solution examines hydration strategies to mitigate nephrotoxicity, enhancing therapeutic outcomes. This study is pivotal in optimizing Methotrexate use in clinical settings, ensuring higher safety and efficacy for patients undergoing chemotherapy (Hasanpour et al., 2024).


法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Met. Corr. 1 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

51.8 °F - closed cup

閃點(°C)

11 °C - closed cup


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Josef S Smolen et al.
Lancet (London, England), 383(9914), 321-332 (2013-10-31)
Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early
Daniel H Solomon et al.
The American journal of medicine, 126(8), 730-730 (2013-07-28)
Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). Subjects with rheumatoid
James R O'Dell et al.
The New England journal of medicine, 369(4), 307-318 (2013-06-13)
Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate--a common scenario in the management of rheumatoid arthritis. We
Richard Conway et al.
Arthritis & rheumatology (Hoboken, N.J.), 66(4), 803-812 (2014-04-24)
Methotrexate has shown efficacy for the treatment of several diseases, especially rheumatoid arthritis (RA). Methotrexate has also been implicated as a causative agent in interstitial lung disease. Patients with RA may develop pulmonary manifestations of their disease and are at

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门